Small molecule myeloperoxidase (mpo) inhibition prevents delayed cerebral injury (dci) after subarachnoid hemorrhage (sah) in a murine model

HIGHLIGHTS

• What: The authors investigate whether AZD5904, a potent MPOi, administered after the onset of SAH is a plausible agent for translation to human studies in patients with SAH. relevant) and before peak meningeal infiltration (day 3: to increase the impact of the therapy and to mimic a human administration regimen). Because this study was focused on validating a small_molecule inhibitor, the authors felt this was warranted.
• Who: Safiye Limon from the All experiments were approved by the Animal Care and Use Committee at the University of VirginiaC BL/, J mice weighing, g and, weeks of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.